— Conference Call Scheduled for

4:30 p.m. ET

–

SAN DIEGO


,


April 25, 2022


/PRNewswire/ — Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2022 as follows:

Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call using

About Evofem Biosciences


Evofem

Biosciences, Inc., (

Nasdaq

:

EVFM

) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (

chlamydia

and gonorrhea). The Company’s first FDA-approved product,

Phexxi

® (lactic acid, citric acid and potassium

bitartrate

), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at


phexxi.com


and


evofem.com


.

Phexxi

^®

is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact



Amy Raskopf


Evofem Biosciences, Inc.


[email protected]


Mobile: (917) 673-5775

Media Contact


Jack Hirschfield

Evofem Biosciences


[email protected]


Mobile: (512) 674-5163

View original content to download multimedia:

https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-first-quarter-2022-results-and-provide-corporate-update-on-wednesday-may-4-2022-301531647.html

SOURCE Evofem Biosciences, Inc.